脑癌护理协调员对胶质母细胞瘤患者医疗服务利用率和疗效的影响

IF 2.4 Q2 CLINICAL NEUROLOGY

Neuro-oncology practice Pub Date : 2024-05-04 DOI:10.1093/nop/npae030

Martin Hong, Lucy Leigh, Connor Ballinger, Penny Reeves, Alisha Gooley, Sandy Nixon, Chris Paul, J. Lynam

{"title":"脑癌护理协调员对胶质母细胞瘤患者医疗服务利用率和疗效的影响","authors":"Martin Hong, Lucy Leigh, Connor Ballinger, Penny Reeves, Alisha Gooley, Sandy Nixon, Chris Paul, J. Lynam","doi":"10.1093/nop/npae030","DOIUrl":null,"url":null,"abstract":"\n \n \n Cancer care coordinators (CCCs) are recognised as having an important role in patients’ and carers’ cancer journey. However, there are no studies investigating the impact of CCCs on quantitative outcomes. We performed a retrospective cohort study investigating the impact of Brain Cancer Care Coordinators (BCCCs) on health service resource use and survival in patients with glioblastoma.\n \n \n \n All patients diagnosed with glioblastoma between 2012 and 2019 in Hunter New England Local Health District, Australia (HNELHD) were included and the patients were divided into two cohorts: before and after introduction of the BCCC. Any patient diagnosed in 2016, during the introduction of the BCCC, were excluded. Main outcomes assessed were overall survival, health service resource use, odds of being admitted to hospital after emergency presentation, and cost-offset analysis to examine the economic implications of BCCCs.\n \n \n \n A total of 187 patients were included. There were no significant differences in overall survival between the two groups (mOS 12.0 vs 11.16 months, HR 0.95). However, there was a reduction in the number of ED presentations and admissions. This was associated with a 24% reduction in aggregate length of stay with the BCCC. There was no statistically significant difference in mean patient costs, however our hospital may have saved over AUD$500,000 with BCCCs.\n \n \n \n The introduction of BCCC did not improve survival but appeared to be associated with reduced health resource utilisation. This study provides economic justification, in addition to established quality of life improvements, to support the presence of BCCCs.\n","PeriodicalId":19234,"journal":{"name":"Neuro-oncology practice","volume":null,"pages":null},"PeriodicalIF":2.4000,"publicationDate":"2024-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The Impact of Brain Cancer Care Coordinators on Healthcare Utilisation and Outcomes in Patients with Glioblastoma\",\"authors\":\"Martin Hong, Lucy Leigh, Connor Ballinger, Penny Reeves, Alisha Gooley, Sandy Nixon, Chris Paul, J. Lynam\",\"doi\":\"10.1093/nop/npae030\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\\n \\n \\n Cancer care coordinators (CCCs) are recognised as having an important role in patients’ and carers’ cancer journey. However, there are no studies investigating the impact of CCCs on quantitative outcomes. We performed a retrospective cohort study investigating the impact of Brain Cancer Care Coordinators (BCCCs) on health service resource use and survival in patients with glioblastoma.\\n \\n \\n \\n All patients diagnosed with glioblastoma between 2012 and 2019 in Hunter New England Local Health District, Australia (HNELHD) were included and the patients were divided into two cohorts: before and after introduction of the BCCC. Any patient diagnosed in 2016, during the introduction of the BCCC, were excluded. Main outcomes assessed were overall survival, health service resource use, odds of being admitted to hospital after emergency presentation, and cost-offset analysis to examine the economic implications of BCCCs.\\n \\n \\n \\n A total of 187 patients were included. There were no significant differences in overall survival between the two groups (mOS 12.0 vs 11.16 months, HR 0.95). However, there was a reduction in the number of ED presentations and admissions. This was associated with a 24% reduction in aggregate length of stay with the BCCC. There was no statistically significant difference in mean patient costs, however our hospital may have saved over AUD$500,000 with BCCCs.\\n \\n \\n \\n The introduction of BCCC did not improve survival but appeared to be associated with reduced health resource utilisation. This study provides economic justification, in addition to established quality of life improvements, to support the presence of BCCCs.\\n\",\"PeriodicalId\":19234,\"journal\":{\"name\":\"Neuro-oncology practice\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.4000,\"publicationDate\":\"2024-05-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Neuro-oncology practice\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1093/nop/npae030\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuro-oncology practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/nop/npae030","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

摘要

癌症护理协调员（CCCs）被认为在患者和护理者的癌症治疗过程中发挥着重要作用。然而，目前还没有研究调查癌症护理协调员对量化结果的影响。我们进行了一项回顾性队列研究，调查脑癌护理协调员（BCCs）对胶质母细胞瘤患者医疗服务资源使用和存活率的影响。研究纳入了澳大利亚猎人新英格兰地方卫生区（HNELHD）2012年至2019年期间确诊的所有胶质母细胞瘤患者，并将患者分为两个队列：引入BCC之前和之后。任何在2016年（BCC引入期间）确诊的患者均被排除在外。评估的主要结果包括总体生存率、医疗服务资源使用情况、急诊后入院的几率，以及成本抵消分析，以研究 BCCC 的经济影响。共纳入了187名患者。两组患者的总生存期无明显差异（mOS 12.0 个月 vs 11.16 个月，HR 0.95）。不过，急诊室就诊和入院人数有所减少。这与 BCCC 的总住院时间减少 24% 有关。患者的平均费用在统计学上没有明显差异，但我们医院使用 BCCC 可能节省了 50 多万澳元。 BCCC 的引入并没有提高生存率，但似乎与医疗资源利用率的降低有关。除了已经确定的生活质量改善之外，本研究还提供了经济方面的理由来支持 BCCC 的存在。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

The Impact of Brain Cancer Care Coordinators on Healthcare Utilisation and Outcomes in Patients with Glioblastoma

Cancer care coordinators (CCCs) are recognised as having an important role in patients’ and carers’ cancer journey. However, there are no studies investigating the impact of CCCs on quantitative outcomes. We performed a retrospective cohort study investigating the impact of Brain Cancer Care Coordinators (BCCCs) on health service resource use and survival in patients with glioblastoma. All patients diagnosed with glioblastoma between 2012 and 2019 in Hunter New England Local Health District, Australia (HNELHD) were included and the patients were divided into two cohorts: before and after introduction of the BCCC. Any patient diagnosed in 2016, during the introduction of the BCCC, were excluded. Main outcomes assessed were overall survival, health service resource use, odds of being admitted to hospital after emergency presentation, and cost-offset analysis to examine the economic implications of BCCCs. A total of 187 patients were included. There were no significant differences in overall survival between the two groups (mOS 12.0 vs 11.16 months, HR 0.95). However, there was a reduction in the number of ED presentations and admissions. This was associated with a 24% reduction in aggregate length of stay with the BCCC. There was no statistically significant difference in mean patient costs, however our hospital may have saved over AUD$500,000 with BCCCs. The introduction of BCCC did not improve survival but appeared to be associated with reduced health resource utilisation. This study provides economic justification, in addition to established quality of life improvements, to support the presence of BCCCs.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Neuro-oncology practice CLINICAL NEUROLOGY-

CiteScore

5.30

自引率

11.10%

发文量

期刊介绍： Neuro-Oncology Practice focuses on the clinical aspects of the subspecialty for practicing clinicians and healthcare specialists from a variety of disciplines including physicians, nurses, physical/occupational therapists, neuropsychologists, and palliative care specialists, who have focused their careers on clinical patient care and who want to apply the latest treatment advances to their practice. These include: Applying new trial results to improve standards of patient care Translating scientific advances such as tumor molecular profiling and advanced imaging into clinical treatment decision making and personalized brain tumor therapies Raising awareness of basic, translational and clinical research in areas of symptom management, survivorship, neurocognitive function, end of life issues and caregiving